Participants in the British study comparing first-generation antipsychotics (FGAs) with second-generation antipsychotics (SGAs) were randomized to receive either an FGA or an SGA.

FGAs used in the trial:

• chlorpromazine

• flupenthixol^FN1

• haloperidol

• loxapine

• methotrimeprazine^FN1

• sulpiride^FN1

• trifluoperazine

• zuclopenthixol^FN1

• fluphenazine decanoate

• flupentixol decanoate^FN1

• haloperidol decanoate

• pipothiazine palmitate^FN1

• zuclopenthixol decanoate^FN1

*

Products not available in the United States.

Thioridazine hydrochloride and droperidol were also included initially but were withdrawn from licensed use during the trial.

SGAs used in the trial:

• risperidone

• olanzapine

• quetiapine

• amisulpride^FN1

• zotepine^FN1